Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
Socialite Jasmine Hartin has been seen enjoying a beach snuggle with her new mystery man.Ms Hartin w2024-05-21Chinese collage offers spring break, encourages outings, love
(ECNS) -- A higher vocational school in southwest China’s Sichuan Province on Wednesday scheduled a2024-05-21Lao PM says China taking concrete actions to deepen global anti
Chinese ambassador to Laos Jiang Zaidong (R) hands over a box of vaccines to Lao Prime Minister Phan2024-05-21World political party leaders hail CPC's people
Cyril Ramaphosa, president of the African National Congress and South African president, addresses t2024-05-21Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
Jessica Biel unveiled a dramatic hair transformation - from chest-length locks to a short bob - on S2024-05-21China's foreign trade rebounds amid stronger economic recovery momentum
BEIJING, June 9 (Xinhua) -- China's foreign trade rebounded in May, a sign of overall recovery as th2024-05-21
atest comment